EGFR and metastatic colorectal cancer: Patients with metastatic colorectal cancer (mCRC), harboring RAS mutations, do not benefit from anti‐epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) such as cetuximab and panitumumab (Sorich et al., 2015).